Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 22 Feb 2022
The truth about patient access and FDA fast tracking
21 February 2022 - University of Illinois Chicago researchers studied 135 products that received U.S. FDA approval through orphan drug and ...
Posted by Michael Wonder on 22 Feb 2022
TGA approves Rybelsus
22 February 2022 - Rybelsus is a new formulation of semaglutide. ...
Posted by Michael Wonder on 21 Feb 2022
Bayer’s new treatment Kerendia (finerenone) approved in EU for adult patients with chronic kidney disease associated with type 2 diabetes
21 February 2022 - Kerendia is the first non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate positive kidney and cardiovascular outcomes in ...
Posted by Michael Wonder on 21 Feb 2022
Proposed PMPRB regulations requires focused dialogue with all players
16 February 2022 - Canada needs an approach that balances pricing considerations with the need to encourage investment, foster innovation, and ...
Posted by Michael Wonder on 21 Feb 2022
Apple iPhone game changing new health feature cleared by FDA, coming in weeks
20 February 2022 - A new app is coming this spring which will be game changing for diabetes care. ...
Posted by Michael Wonder on 21 Feb 2022
Responses to Prostheses List reform
16 February 2022 - Consultation paper #3 A modernised fit for purpose listing process was released on 11 January and closes ...
Posted by Michael Wonder on 21 Feb 2022
Drug funded for people with spinal muscular atrophy
15 February 2022 - The provincial government is covering costs for risdiplam, or Evrysdi, the medication used to treat a severe ...
Posted by Michael Wonder on 21 Feb 2022
U.S. FDA approves FoundationOne CDx as a companion diagnostic for Keytruda (pembrolizumab) to identify patients with microsatellite instability-high solid tumours
21 February 2022 - Foundation Medicine’s tissue-based comprehensive genomic profiling test is now the first and only FDA approved companion diagnostic ...
Posted by Michael Wonder on 21 Feb 2022
PBS arrangements for medicines for the treatment of paroxysmal nocturnal haemoglobinuria
21 February 2022 - Commencing 1 March 2022, Soliris (eculizumab) and Ultomiris (ravulizumab) will be listed on the Pharmaceutical Benefits Scheme ...
Posted by Michael Wonder on 21 Feb 2022
Allarity Therapeutics receives refusal to file letters from U.S. FDA
18 February 2022 - Allarity intends to seek guidance from the FDA on how to further advance dovitinib and its ...
Posted by Michael Wonder on 21 Feb 2022
COVID-19 pandemic sends clear message that Australia must value the long-term health of all Australians
21 February 2022 - Medicines Australia is warning that Australia must act now to ensure that our health system is ...
Posted by Michael Wonder on 20 Feb 2022
New PBS listing to help fight chronic graft versus host disease
20 February 2022 - From 1 March 2022, Australians with chronic graft versus host disease, a complication that can occur when ...
Posted by Michael Wonder on 20 Feb 2022
Assessing transferability in systematic reviews of health economic evaluations – a review of methodological guidance
20 February 2022 - For assessing cost effectiveness, health technology assessment organisations may use primary economic evaluations or systematic reviews of ...
Posted by Michael Wonder on 20 Feb 2022
Stabilising health care’s share of the GDP
19 February 2022 - Since the 1980s, policy makers and private health insurers have implemented various interventions aimed at “bending the ...
Posted by Michael Wonder on 20 Feb 2022
BioNTech plans to make vaccines in shipping containers
19 February 2022 - These standardised factories could be quickly scaled up to expand capacity worldwide. ...